ZYDUS LIFESCIENCES
|
ZYDUS LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 38.36 | 19.37 | 43.82 | 20.84 | 11.49 |
| CEPS(Rs) | 45.68 | 26.92 | 29.68 | 28.08 | 18.28 |
| DPS(Rs) | 3.00 | 6.00 | 2.50 | 3.50 | 3.50 |
| Book NAV/Share(Rs) | 197.11 | 173.08 | 166.01 | 126.88 | 101.33 |
| Tax Rate(%) | 20.33 | 22.70 | 18.03 | 8.07 | 21.39 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.97 | 10.53 | 10.74 | 11.72 | 19.51 |
| EBIT Margin(%) | 12.89 | 8.02 | 10.03 | 8.96 | 12.89 |
| Pre Tax Margin(%) | 12.68 | 7.64 | 9.60 | 8.31 | 10.49 |
| PAT Margin (%) | 10.10 | 5.90 | 7.87 | 7.64 | 8.25 |
| Cash Profit Margin (%) | 12.12 | 8.03 | 10.28 | 9.96 | 13.13 |
| Performance Ratios | |||||
| ROA(%) | 14.70 | 7.82 | 9.40 | 9.66 | 5.18 |
| ROE(%) | 20.52 | 11.60 | 15.51 | 18.88 | 11.32 |
| ROCE(%) | 24.90 | 13.64 | 15.30 | 14.38 | 10.02 |
| Asset Turnover(x) | 1.46 | 1.32 | 1.19 | 1.27 | 0.63 |
| Sales/Fixed Asset(x) | 1.98 | 1.88 | 1.69 | 1.69 | 0.88 |
| Working Capital/Sales(x) | 6.24 | 7.57 | 6.92 | 33.78 | 31.96 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.50 | 0.53 | 0.59 | 0.59 | 1.14 |
| Receivable days | 46.37 | 41.75 | 39.94 | 42.92 | 97.49 |
| Inventory Days | 32.98 | 38.39 | 42.95 | 38.08 | 70.13 |
| Payable days | 147.51 | 145.80 | 166.64 | 189.45 | 170.61 |
| Valuation Parameters | |||||
| PER(x) | 26.20 | 25.37 | 7.96 | 21.16 | 23.25 |
| PCE(x) | 22.01 | 18.26 | 11.75 | 15.70 | 14.61 |
| Price/Book(x) | 5.10 | 2.84 | 2.10 | 3.47 | 2.64 |
| Yield(%) | 0.30 | 1.22 | 0.72 | 0.79 | 1.31 |
| EV/Net Sales(x) | 5.16 | 2.92 | 2.57 | 3.39 | 2.41 |
| EV/Core EBITDA(x) | 17.78 | 12.44 | 10.88 | 14.11 | 11.87 |
| EV/EBIT(x) | 20.61 | 18.51 | 13.08 | 18.89 | 18.72 |
| EV/CE(x) | 4.89 | 2.69 | 1.45 | 2.14 | 1.51 |
| M Cap / Sales | 5.17 | 2.89 | 2.36 | 3.13 | 1.92 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.40 | 14.08 | 4.90 | 1.06 | 8.26 |
| Core EBITDA Growth(%) | 40.08 | 13.49 | 3.04 | 19.43 | -9.09 |
| EBIT Growth(%) | 79.81 | -8.28 | 14.68 | 40.74 | -28.73 |
| PAT Growth(%) | 91.39 | -13.95 | 5.48 | 87.61 | -36.52 |
| EPS Growth(%) | 98.06 | -55.80 | 110.32 | 81.34 | -36.36 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.04 | 0.07 | 0.25 | 0.35 | 0.77 |
| Current Ratio(x) | 2.14 | 1.81 | 1.55 | 1.11 | 1.05 |
| Quick Ratio(x) | 1.50 | 1.19 | 1.07 | 0.70 | 0.72 |
| Interest Cover(x) | 60.22 | 20.94 | 23.35 | 13.87 | 5.38 |
| Total Debt/Mcap(x) | 0.01 | 0.02 | 0.12 | 0.10 | 0.29 |
Compare Financial Ratios of peers of ZYDUS LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ZYDUS LIFESCIENCES | ₹107,210.6 Cr | 1.4% | -4.2% | 76% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,342.0 Cr | -0.2% | 3% | 68% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,028.0 Cr | 13.7% | 12.9% | 60.4% | Stock Analytics | |
| CIPLA | ₹128,832.0 Cr | -1.8% | -2% | 39.6% | Stock Analytics | |
| MANKIND PHARMA | ₹111,956.0 Cr | 9.2% | 14.8% | 51.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹110,160.0 Cr | -0.1% | -0.2% | 19.8% | Stock Analytics | |
ZYDUS LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ZYDUS LIFESCIENCES | 1.4% |
-4.2% |
76% |
| SENSEX | -0.4% |
-0.7% |
23.3% |
You may also like the below Video Courses
